Drugs / Diltiazem ER
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00983372 | Aug 2008 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diltiazem ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00983372 ↗ |
| Action | Inhibit | “Extended-release diltiazem (diltiazem ER) is a potent inhibitor of both CYP3A4 and P-gp.” NCT00983372 ↗ |
| Target | CYP3A4 | “Extended-release diltiazem (diltiazem ER) is a potent inhibitor of both CYP3A4 and P-gp.” NCT00983372 ↗ |